Apollo Therapeutics is a portfolio biotech company that develops a broad range of drug programs to generate value for its stakeholders. It has a diversified clinical-stage portfolio of assets focused on high-value markets, with over 20 programs in its core areas of biological focus, including cell signaling, cell stress response, and immunology.

Ian Tomlinson

Apollo Therapeutics

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. 

Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.

Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. 

For more information, please visit our website at www.apollotherapeutics.com

UCLB

Rock Springs Capital

Patient Square Capital

M&G Plc

Reimagined Ventures

UCL Technology Fund

Our CEO Richard Mason will be presenting an overview of Apollo Therapeutics at the Evercore ISI 2024 Emerging Biotech Conference tomorrow (Thursday, February 29) at 10:45 – 11:15 ET.
#biotech  #conference 


Apollo Therapeutics will be attending the Cowen Inc. 44th Annual Health Care Conference in Boston, US next week from March 4-6. Our CEO Richard Mason and CFO Jamie Heath will be hosting one-on-one meetings on Tuesday, March 5 - meeting slots can be booked via Cowen or please do let us know directly if you would like to connect at the conference.
 
We look forward to seeing you there!
 #biotech #conference 


We are delighted to have completed the second close of our Series C financing in December 2023, bringing the total raised in this round by the Company to $260m. 
 
The Series C financing was led by Patient Square Capital and included participation by multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investors including Rock Springs Capital.
 
This fundraise means we can continue to progress our broad and diversified pipeline of over 20 uncorrelated therapeutic programs, with multiple assets about to enter the clinic in early 2024.
	 
#seriesc #biotech #fundraising 

Metric
Company Name	Apollo Therapeutics
Symbol
MSH ID	COM:APOLLOTHERAPEUTICS
Market	PRIVATE
Sector	8
Industry	Healthcare & Health Services
Country
Stage
Employee Count	52
Website	apollotherapeutics.com
LinkedIn	apollo-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:APOLLOTHERAPEUTICS

Apollo Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue